Roche Pharma teams up with 10 Govt Hospitals to power up clinical trial capacities in India

Written by Ruchika Sharma Published On 2025-09-15T11:53:00+05:30 | Updated On 15 Sept 2025 11:53 AM IST

No Waiver for Faricimab: CDSCO Panel Asks Roche to Conduct Phase III Trial in India

New Delhi: Roche Pharma has announced that it has joined hands with ten government hospitals to strengthen India's clinical trial ecosystem.

Under this initiative, nearly 400 professionals—including investigators, ethics committee members, and other resources—have been trained as per global Good Clinical Practice (GCP) standards, PTI reported.

"By equipping leading government hospitals with global-standard clinical trial capabilities, we are helping to bring innovations faster to India. This is a crucial step toward building equitable healthcare and shaping treatments that are relevant for India," said Sivabalan Sivanesan, Country Medical Director, Roche Pharma India.

The Advanced Inclusive Research (AIR) Site Alliance is Roche's flagship global initiative designed to expand access to clinical trials for underrepresented populations.

Already implemented in the US, the UK, Canada, and Africa, the AIR Site Alliance is now active in India.

India accounts for 17 per cent of the world's population and 20 per cent of the global disease burden, yet fewer than 4 per cent of global clinical trials are conducted in the country.

The Initiative aligns with CDSCO priorities to boost participation of government sites in Phase 3 and 4 trials.

In March last year, Roche Pharma India forayed into the Ophthalmology space by launching Vabysmo (faricimab) for the treatment of eye diseases.

Neovascular or wet age-related macular degeneration (nAMD) and diabetic macular edema (DME), are two leading causes of vision loss worldwide.

Vabysmo is the dual-pathway-inhibitor that uniquely targets and inhibits two disease pathways linked to a number of vision threatening retinal conditions.

It neutralises both angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) which are key proteins involved in the development and progression of retinal conditions, contributing to vision loss by destabilising blood vessels in the eye.

roche pharmagovernment hospitalclinical trial

Source : With inputs

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751